Introduction {#tca12906-sec-0001}
============

Human epidermal growth factor 2 (HER2, erbB‐2/neu) is a member of the erbB receptor tyrosine kinase family. It is a plasma membrane‐bound receptor tyrosine kinase, containing extracellular ligand binding, transmembrane, and intracellular domains*. HER2* is activated by homodimerization or heterodimerization with other erbB‐2 family members, especially *EGFR*.[1](#tca12906-bib-0001){ref-type="ref"}, [2](#tca12906-bib-0002){ref-type="ref"} *HER2* combined with *EGFR* can increase the potential for receptor phosphorylation and thus activate downstream signaling pathways, including mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase (PI3K/Akt), phospholipase C γ, protein kinase C (PKC), and signal transducer and activator of transcription (STAT). These signaling pathways promote cell proliferation and resist apoptosis, which is correlated to uncontrolled cell growth in oncogenesis.[3](#tca12906-bib-0003){ref-type="ref"}, [4](#tca12906-bib-0004){ref-type="ref"} The principal mechanisms of oncogenic activation of HER2 are *HER2* gene amplification, gene mutation, and HER2 protein overexpression.[5](#tca12906-bib-0005){ref-type="ref"} Oncogenic activity of *HER2* mutations have been reported in a large spectrum of malignancies including breast, ovarian, bladder, salivary gland, endometrial, pancreatic, and non‐small cell lung cancers.[6](#tca12906-bib-0006){ref-type="ref"}

Afatinib is an oral HER family blocker, which can covalently bind and irreversibly block ErbB receptor family members.[7](#tca12906-bib-0007){ref-type="ref"} It displays a manageable toxicity profile and promising results in several retrospective studies targeting mutated *HER2* exon 20 in non‐small cell lung cancer (NSCLC).[5](#tca12906-bib-0005){ref-type="ref"}

Herein, we report a stage IV lung adenocarcinoma patient harboring a *HER2* exon 20 inserted mutation who was treated with afatinib as first‐line treatment and achieved progression‐free survival (PFS) of 12 months with ongoing treatment. To the best of our knowledge, this is the first report of first‐line afatinib treatment achieving a partial response (PR) in an NSCLC patient with a *HER2* exon 20 insertion mutation.

Case report {#tca12906-sec-0002}
===========

A 57‐year‐old, non‐smoking woman was diagnosed with stage IV lung adenocarcinoma in July 2017 after undergoing a left pleural biopsy by wedge resection of the lower lobe of the left lung. The tumor node metastasis (TNM) classification of this patient was T3aN0M1a, because of ipsilateral lobe and pleural metastases. The pathological result from lung tissue biopsy was infiltrating lung adenocarcinoma. Immunohistochemical results showed positive thyroid transcription factor‐1 (TTF‐1), negative *ALK*, cytokeratin (CK)‐7, and CK‐10. No intracranial metastasis was observed on brain magnetic resonance imaging. A mutation frequency of 28.2% exon 20 ERBB2 activated mutation (p.G776delinsVC) was found in the tumor DNA extracted from the original diagnostic biopsy by next‐generation sequencing (NGS), performed by Cancer‐Hope (Genomicare, Shanghai, China). A CTNNB1 with p.S45P activated mutation was also detected at a frequency of 16.03%. Testing was conducted to identify any other common mutations, such as *EGFR*, *KRAS*, *NRAS*, *MET*, *ALK*, *ROS1*, and *RET*, however, the results were negative. The patient had not previously been administered chemotherapy or targeted therapy.

Treatment with afatinib (40mg/day) was commenced in August 2017. One month later, computed tomography showed a radiological PR with the patient advising relief of the chest pain (Fig [1](#tca12906-fig-0001){ref-type="fig"}). She was followed‐up at outpatient visits every two months and achieved a continuous PR until July 2018, the latest return visit. Afatinib treatment is ongoing. The major treatment‐related side effects observed were diarrhea, oral ulcers, and grade 1 skin adverse events.

![(**a,b**) Computed tomography (CT) images taken on 28 July 2017 when the patient arrived at our outpatient facility for the first time. Multiple lesions were observed on both sides of the lung. (**c,d**) CT images taken on 27 August 2017 after orally administration of afatinib 40 mg/day for one month. Shrinkage of the lesions was observed, particularly in the upper lobe of the left lung.](TCA-9-1788-g001){#tca12906-fig-0001}

Discussion {#tca12906-sec-0003}
==========

*HER2* kinase domain mutation occurs in 1--4% of lung adenocarcinomas as oncogenic driver mutations.[8](#tca12906-bib-0008){ref-type="ref"} Oncogenic mutations of *HER2* mostly present in non‐smoking female patients diagnosed with advanced lung adenocarcinoma.[9](#tca12906-bib-0009){ref-type="ref"}, [10](#tca12906-bib-0010){ref-type="ref"}, [11](#tca12906-bib-0011){ref-type="ref"}, [12](#tca12906-bib-0012){ref-type="ref"}, [13](#tca12906-bib-0013){ref-type="ref"}, [14](#tca12906-bib-0014){ref-type="ref"} Similar to *EGFR* mutations in NSCLC, *HER2* mutations most frequently occur in tyrosine kinase domains, but cases involving the extracellular domain and transmembrane domain (TMD) have been reported.[15](#tca12906-bib-0015){ref-type="ref"} The most common subtype of *HER2* mutation is exon 20 in‐frame YVMA insertion (*HER2*\[YMVA\]), which is found in over 50% of all *HER2* mutant lung cancer patients.[12](#tca12906-bib-0012){ref-type="ref"} The percentage of exon 20 in‐frame insertions has been reported to be as high as 89--100% by several large cohort studies.[13](#tca12906-bib-0013){ref-type="ref"}, [14](#tca12906-bib-0014){ref-type="ref"}, [16](#tca12906-bib-0016){ref-type="ref"}, [17](#tca12906-bib-0017){ref-type="ref"}, [18](#tca12906-bib-0018){ref-type="ref"} Gow *et al*. retrospectively analyzed 888 Asian lung cancer patients via gene sequencing to detect a number of driver gene mutations, including *HER2*. Forty lung adenocarcinoma patients were *HER2* mutation positive and all were exon 20 insertion alterations. A775_G776ins YVMA and P780_Y781insGSP were the two most prevalent mutation subtypes (*n* = 22 and *n* = 4, respectively).[19](#tca12906-bib-0019){ref-type="ref"}

Afatinib exhibits antitumor efficacy by downregulating the phosphorylation of HER2 and EGFR, together with downstream signaling in *HER2* mutant NSCLC. Moreover, it induces an anti‐proliferative effect through G1 arrest and apoptotic cell death.[20](#tca12906-bib-0020){ref-type="ref"} Increased *HER2* phosphorylation, as well as increased sensitivity to afatinib, have also been observed in transfected Ba/F3 cells with *HER2* (P780_Y781insGSP) mutation, indicating the possible treatment efficacy of afatinib.[21](#tca12906-bib-0021){ref-type="ref"}

De Greve *et al*. reported the first evidence of clinical benefit from afatinib treatment in 2011.[22](#tca12906-bib-0022){ref-type="ref"} Three patients diagnosed with advanced lung adenocarcinoma were detected with *HER2* mutations. They were administered afatinib 50 mg/day (2 accompanied by paclitaxel) and all achieved significant tumor regression, with an afatinib‐related PFS of 3--15 months. De Greve *et al*. subsequently conducted a phase II clinical study to evaluate the effects of afatinib or afatinib plus paclitaxel for the treatment of lung adenocarcinoma. Notably, one patient receiving afatinib monotherapy achieved a confirmed PR, as well as one patient treated with combination therapy who had a confirmed PR of 41.9 weeks.[23](#tca12906-bib-0023){ref-type="ref"} Since these studies, few cases of lung adenocarcinoma patients harboring *HER2* mutation have been reported (Table [1](#tca12906-tbl-0001){ref-type="table"}). Of the 24 reported cases (F: 16 vs. M: 8), three patients were light smokers, one male patient was a heavy smoker, and the remaining 15 patients were never‐smokers (5 were unclear). Seventeen (71%) patients' genetic sequences were altered with exon 20 insertions. Five harbored TMD mutations and also responded to afatinib, with no significant difference to those with exon 20 insertions. Unlike other patients who were treated with no more than 50 mg/day afatinib, three patients underwent pulse afatinib therapy with oral 280mg once a week. It is worth mentioning that these three patients did not experience any rash, which is a common drug‐related side effect of afatinib. The PFS durations were 11 and 5 months; PFS was not available in the third patient.[25](#tca12906-bib-0025){ref-type="ref"} Twenty patients achieved evaluable afatinib‐related PR or stable disease (SD), with a median PFS of 5.25 months (range: 1--18).

###### 

Summary of afatinib efficacy for the treatment of advanced lung adenocarcinoma harboring *HER2* mutation

  No.                                                                                                         Age, y                        Gender  Smoking status     Histologic subtype              Stage                *ERBB2*/*HER2* Alteration                              Systemic Therapy                            Best Response                                            PFS
  -------------------------------------------------------------------------------------- ------------------------------------------------- -------- ------------------ ------------------------------- -------------------- ------------------------------------------------------ ------------------------------------------- -------------------------------------------------------- ----------
  1[22](#tca12906-bib-0022){ref-type="ref"}                                                                     72                            F     Never              Lung ADC                        III                  Exon 20 mutation (p.Tyr772_Ala775dup)                  Carbo/Gem X8 cycles                         Partial remission then SD                                3 mo
  Afatinib \*3 mo                                                                                           PR then PD                                                                                                                                                                                                                                                                  
  2[22](#tca12906-bib-0022){ref-type="ref"}                                                                     62                            F     Never              Lung ADC                        pT2N1                Exon 20 mutation (p.Gly776Leu)                         After surgery                                                                                        8 mo
  Cis/Gem \*4 cycles                                                                                            SD                                                                                                                                                                                                                                                                      
  Docetaxel \*6 cycles                                                                                          SD                                                                                                                                                                                                                                                                      
  Gefitinib                                                                                                     PD                                                                                                                                                                                                                                                                      
  Tras/Paclitaxel                                                                                               PR                                                                                                                                                                                                                                                                      
  Lapatinib                                                                                                     NA                                                                                                                                                                                                                                                                      
  Gem                                                                                                           NA                                                                                                                                                                                                                                                                      
  vinorelbine                                                                                                   NA                                                                                                                                                                                                                                                                      
  Afatinib \*4 mo                                                                                               PR                                                                                                                                                                                                                                                                      
  Afatinib/Paclitaxel \*4 mo                                                                                    PR                                                                                                                                                                                                                                                                      
  3[22](#tca12906-bib-0022){ref-type="ref"}                                                                     49                            F     Never              Lung ADC                        IV                   Exon 20 insertional duplication (p.Gly778_Pro780dup)   Erlo\*3 mo                                  PD                                                       15 mo
  Cis/Gem                                                                                               Objective response                                                                                                                                                                                                                                                              
  Gem                                                                                                           PD                                                                                                                                                                                                                                                                      
  Carbo                                                                                                 Transient response                                                                                                                                                                                                                                                              
  Vinorelbine                                                                                                   PD                                                                                                                                                                                                                                                                      
  Peme                                                                                                  Transient response                                                                                                                                                                                                                                                              
  Cis                                                                                                   Objective response                                                                                                                                                                                                                                                              
  Afatinib\*4 mo                                                                                                PR                                                                                                                                                                                                                                                                      
  Afatinib/Paclitaxel \*11 mo                                                                                   PR                                                                                                                                                                                                                                                                      
  4[23](#tca12906-bib-0023){ref-type="ref"}                                                                     48                            F     Never              Lung ADC                        IV                   Exon 20 mutation (P780_Y781insGSP)                     Peme/Cis \*6 cycles                         PR                                                       4 mo
  Paclitaxel \*2 cycles                                                                                         PD                                                                                                                                                                                                                                                                      
  Gem/Cis \*8 cycles                                                                                   SD for first 4 cycles                                                                                                                                                                                                                                                            
  Afatinib \*4 mo                                                                                               PR                                                                                                                                                                                                                                                                      
  5[24](#tca12906-bib-0024){ref-type="ref"}                                                                     55                            M     Never              Lung ADC                        IV                   Exon 20 mutation (p.A775_G776insYVMA)                  Carbo/Gem/Beva \*5 mo                       PR                                                       10 mo
  maintenance Beva \*13mo                                                                                       PD                                                                                                                                                                                                                                                                      
  Erlo/Pertuzumab \*2 mo                                                                                        SD                                                                                                                                                                                                                                                                      
  Peme \*5 mo                                                                                                   SD                                                                                                                                                                                                                                                                      
  Docetaxel \*8 mo                                                                                              SD                                                                                                                                                                                                                                                                      
  Dacomitinib/Placebo \*2 mo                                                                                    PD                                                                                                                                                                                                                                                                      
  Afatinib \*10 mo                                                                                              PR                                                                                                                                                                                                                                                                      
  6[25](#tca12906-bib-0025){ref-type="ref"}                                                                     65                            M     Never              Lung ADC                        IV                   Exon 20 insertion (A775_G776insYVMA)                   Carbo/Peme \*5 mo                           SD                                                       
  Neratinib/temsirolimus \*3 mo                                                                                 SD                                                                                                                                                                                                                                                                      
  Brain radiotherapy                                                                                                                                                                                                                                                                                                                                                                    
  Afatinib (280 mg once weekly)                                                                                 NA                                                                                                                                                                                                                                                                      
  7[25](#tca12906-bib-0025){ref-type="ref"}                                                                     64                            F     5‐pack‐year        Lung ADC                        IV                   Exon 20 insertion (V747_G748insGSP)                    Carbo/Peme \*3 mo                           NA                                                       11 mo
  Afatinib (280 mg once weekly) \*11 mo                                                                         PR                                                                                                                                                                                                                                                                      
  8[25](#tca12906-bib-0025){ref-type="ref"}                                                                     71                            F     Never              Lung ADC                        IV                   Exon 20 insertion (E740_A741insAYVM)                   Afatinib (280 mg once weekly) \*5 mo        PR                                                       5 mo
  9[26](#tca12906-bib-0026){ref-type="ref"}                                                                     58                            F     NP                 Solid predominant               NP                   Exon 20 insertion (GSP781‐783ins)                      Gem/cis \*4.6 mo                            SD                                                       5.5 mo
  Afatinib \*5.5 mo                                                                                             SD                                                                                                                                                                                                                                                                      
  10[26](#tca12906-bib-0026){ref-type="ref"}                                                                    70                            F     NP                 Papillary predominant           NP                   Exon 20 insertion (YVMA776‐779ins)                     Peme/carbo\*2.8 mo                          SD                                                       3.5 mo
  Afatinib \*3.5 mo                                                                                             SD                                                                                                                                                                                                                                                                      
  11[26](#tca12906-bib-0026){ref-type="ref"}                                                                    60                            M     NP                 Micropapillary predominant      NP                   Exon 20 insertion (YVMA776‐779ins)                     Afatinib \*4 mo                             SD                                                       4 mo
  12[26](#tca12906-bib-0026){ref-type="ref"}                                                                    66                            M     NP                 Papillary predominant           NP                   Exon 20 insertion (YVMA776‐779ins)                     Docetaxel/platinum \*1 mo                   PD                                                       NA
  Afatinib \*1 mo                                                                                               PD                                                                                                                                                                                                                                                                      
  13[27](#tca12906-bib-0027){ref-type="ref"}                                                                    67                            F     Never              Lung ADC                        NP                   Exon 20 insertion (A775_G776insYVMA)                   Carbo/Pem, then Pem maintenance \*9 mo      PR                                                       1 mo
  Tras/Docetaxel\*8 mo                                                                                          PR                                                                                                                                                                                                                                                                      
  Afatinib \*1 mo                                                                                               SD                                                                                                                                                                                                                                                                      
  14[27](#tca12906-bib-0027){ref-type="ref"}                                                                    36                            F     Never              Lung ADC                        NP                   Exon 20 insertion (exact sequence unknown)             Carbo/Pem/Beva, then maintenance \*4.5 mo   PR                                                       6.5 mo
  Erlotinib \*1 mo                                                                                              PD                                                                                                                                                                                                                                                                      
  Afatinib\*6.5 mo                                                                                              PR                                                                                                                                                                                                                                                                      
  Tras/vinorelbine \*6 mo                                                                                       PR                                                                                                                                                                                                                                                                      
  Tras/Docetaxel\* 4 mo                                                                                         SD                                                                                                                                                                                                                                                                      
  Ado‐tras \*2 mo                                                                                               PD                                                                                                                                                                                                                                                                      
  Nivolumab\*1 mo                                                                                               PD                                                                                                                                                                                                                                                                      
  Etirinotecan pegol \*2 mo                                                                                     PD                                                                                                                                                                                                                                                                      
  Afatinib/Bev \*3 mo                                                                     Mixed response, with SD in lung and PD in liver                                                                                                                                                                                                                                               
  15[28](#tca12906-bib-0028){ref-type="ref"}                                                                    41                            M     Heavy Smoker       Lung ADC                        IV                   HER2 exon 8 S310Y                                      Gem/Carbo \*4 cycle                         NA                                                       7 mo
  c.929C\>A(p.Ser310Tyr)                                                                                    Gem\*3cycle                       NA                                                                                                                                                                                                                                        
                                                                                                          Afatinib\*7 mo                      PR                                                                                                                                                                                                                                        
  16[29](#tca12906-bib-0029){ref-type="ref"}                                                                    50                            F     Never              Lung ADC                        IV                   Exon 20 mutation                                       Peme/Cis \*4cycle                           SD                                                       4 mo
  (c.2437A\>G)                                                                                           Gefitinib \*2 mo                     NA                                                                                                                                                                                                                                        
                                                                                                          Afatinib \*4 mo                     PR                                                                                                                                                                                                                                        
  17[30](#tca12906-bib-0030){ref-type="ref"}, [31](#tca12906-bib-0031){ref-type="ref"}                          56                            F     1,2‐pack‐year                                                                                                                  Peme/Carbo                                  PD                                                       NA
  Afatinib                                                                                                      PR                                                                                                                                                                                                                                                                      
  18[30](#tca12906-bib-0030){ref-type="ref"}                                                                    52                            F     NA                 Adeno of the ampulla of Vater   Metastatic to lung   G660D and S310F                                        Gem/Cis                                     PD                                                       NA
  Afatinib                                                                                                                                                                                                                                                                                                                                                                              
  19[32](#tca12906-bib-0032){ref-type="ref"}                                                                    45                            F     Never              Lung ADC                        Metastatic to bone   HER2 V777_G778insGSP                                   Cis/Peme\*7 mo                              PR                                                       7 mo
  Docetaxel\* 15 mo                                                                                             PR                                                                                                                                                                                                                                                                      
  Vinorelbine/tras \*2 cycles                                                                                   PD                                                                                                                                                                                                                                                                      
  Afatinib\*7 mo                                                                                                PR                                                                                                                                                                                                                                                                      
  20[33](#tca12906-bib-0033){ref-type="ref"}                                                                    62                            F     Never              NSCLC                           NA                   V659E                                                  First‐line afatinib                         PR                                                       5 mo
  21[33](#tca12906-bib-0033){ref-type="ref"}                                                                    54                            M     Never              NSCLC                           NA                   V659E                                                  Second‐line afatinib                        PR                                                       18 mo
  G660R                                                                                                                                                                                                                                                                                                                                                                                 
  22[33](#tca12906-bib-0033){ref-type="ref"}                                                                    73                            M     Never              NSCLC                           NA                   V659E                                                  Third‐line afatinib                         5 mo of symptomatic improvement and metabolic response   5 mo
  23[33](#tca12906-bib-0033){ref-type="ref"}                                                                    53                            M     Positive history   NSCLC                           NA                   G660D                                                  Second‐line afatinib                        PD                                                       10 weeks
  24                                                                                                            57                            F     Never              Lung ADC                        IV                   Exon 20 mutation (p.G776delinsVC)                      First‐line afatinib                         PR                                                       12 mo

ADC, adenocarcinoma; Beva, bevacizumab; Carbo, carboplatin; Cis, cisplatin; Erlo, erlotinib; Gem, gemcitabine; Mo, month(s); NA, not available; NSCLC, non‐small cell lung cancer; PD, progressive disease; Peme, pemetrexed; PFS, progression‐free survival; PR, partial response; SD, stable disease; Tras, trastuzumab.

Three of the 24 patients received afatinib as first‐line therapy, including our patient, who achieved PFS of 12 months with ongoing afatinib therapy. Of the other two patients, one harbored a TMD V659E mutation and the other an exon 20 insertion (YVMA776‐779ins) and both had SD after afatinib treatment. Our patient is the only reported case with an exon 20 YVMA insertion to achieve a continuous PR.

Large cohort studies have reported similar clinical characteristics of lung cancer harboring *HER2* mutations as these case reports. Mazieres *et al*. retrospectively identified 65 NSCLC patients diagnosed with a *HER2* in‐frame insertion in exon 20. Favorable responses were observed, with a 100% disease control rate in patients administered afatinib (*n* = 4, SD or PR).[13](#tca12906-bib-0013){ref-type="ref"} Furthermore, Mazieres *et al*. also conducted the European EUHER2 study to determine the efficacy of multiple drug therapy for *HER2* exon 20 insertion mutated lung adenocarcinoma patients. Eleven patients were treated with afatinib and the median PFS was 3.9 months. No significant advantage of HER2‐TKI treatment was observed compared to traditional chemotherapy.[14](#tca12906-bib-0014){ref-type="ref"}

Although rarely occurring, mutations in the TMD have also attracted research attention. Ou *et al*. prospectively analyzed the tumor cells of 8551 lung adenocarcinoma patients and identified 15 cases of *HER2* TMD mutations (V659E/D, G660D), two of which harbored concurrent *ErbB2* receptor tyrosine kinase 2 gene amplification. Interestingly, three of the four patients with TMD mutations administered first or second‐line afatinib developed partial or metabolic responses for 5--18 months, indicating the potential benefit not only to kinase domain but also TMD mutation patients.[33](#tca12906-bib-0033){ref-type="ref"}

In conclusion, we report the only known case of a patient with the most common YVMA mutation, *HER2* alteration, administered first‐line afatinib to achieve a continuous PR for at least 12months, which is longer than the median PFS (6.9 months) acquired by pemetrexed/cisplatin.[34](#tca12906-bib-0034){ref-type="ref"} Our results, together with two other first‐line afatinib treatment cases, indicate that large cohort studies should be conducted to investigate the efficacy and drug‐related adverse events of first‐line afatinib compared to traditional first‐line chemotherapy with pemetrexed/cisplatin for the treatment of *HER2* positive lung adenocarcinoma patients.
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